Rigrodsky & Long, P.A. Investigates Omthera Pharmaceuticals, Inc. Buyout
30 Maio 2013 - 8:30PM
Business Wire
Rigrodsky & Long, P.A. of Wilmington, Delaware and New York,
announces that it is investigating potential legal claims against
the board of directors of Omthera Pharmaceuticals, Inc. (“Omthera”)
(NASDAQ GM: OMTH), headquartered in Princeton, New Jersey.
Rigrodsky & Long is investigating possible breaches of
fiduciary duties and other violations of law related to Omthera’s
entry into an agreement to be acquired by AstraZeneca PLC (NYSE:
AZN), a global, innovation-driven biopharmaceutical business, for
only $12.70 per share, in a transaction valued at approximately
$323 million.
According to the press release announcing the proposed buyout,
public shareholders of Omthera will receive $12.70 per share in
cash for each share of Omthera they own. The investigation concerns
whether Omthera’s board of directors failed to adequately shop
Omthera and obtain the best possible value for Omthera’s
shareholders before entering into an agreement with AstraZeneca
PLC. According to Yahoo! Finance, at least one analyst has set a
price target for Omthera stock at $15.00.
If you own the common stock of Omthera (NASDAQ GM: OMTH) and
purchased your shares before May 28, 2013, have information, or
would like to learn more about these claims, you can discuss these
matters or ask questions with no obligations by contacting Seth
Rigrodsky or Peter Allocco at (888) 969-4242; or by e-mail to
info@rigrodskylong.com. You can learn more about the Omthera
acquisition at the Rigrodsky & Long website at:
http://www.rigrodskylong.com/investigations/omthera-pharmaceuticals-inc-omth.
About Rigrodsky & Long,
P.A.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware
and Garden City, New York, works on behalf of shareholders in state
and federal courts throughout the United States. Rigrodsky &
Long regularly litigates corporate class action, shareholder
derivative, and direct actions on behalf of institutional
investors, individual investors, and consumers. Our legal
professionals are experts in shareholders rights and corporate
governance litigation and practice in Delaware Chancery Court,
state courts, and federal courts throughout the United States.
About Omthera Pharmaceuticals,
Inc.
Founded in 2008, Omthera Pharmaceuticals, Inc. is an
emerging specialty pharmaceutical company that listed on NASDAQ in
April 2013 (NASDAQ GM: OMTH). Led by a team of experts with
exceptional experience in developing new therapies for lipid
disorders, Omthera is dedicated to developing innovative therapies
for the millions of patients who have elevated triglyceride levels
and increased risk of cardiovascular disease. Omthera currently has
14 employees based in Princeton, New Jersey.
About AstraZeneca PLC
AstraZeneca is a global, innovation-driven biopharmaceutical
business that focuses on the discovery, development and
commercialization of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation,
autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.
© 2013 Rigrodsky & Long, P.A. Attorney advertising. Prior
results do not guarantee a similar outcome.
Tags: Omthera Pharmaceuticals, OMTH, AstraZeneca PLC, AZN,
Rigrodsky & Long
OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
